This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

M. Fran Smith, MD; J. William Doyle, MD, PhD

Arch Ophthalmol. 2001;119:809-812.

Background  Tissue plasminogen activator (tPA) is a serine protease with thrombolytic-fibrinolytic activity. In the anterior segment of the eye, it has been used to lyse blood and fibrin clots immediately following trabeculectomy.

Objective  To review our experience using tPA to revive previously functional but newly failing blebs following secondary surgical procedures (cataract extraction or penetrating keratoplasty).

Methods  A retrospective medical record review of all eyes receiving tPA to revive a failing bleb after a later anterior segment surgery was performed. Blebs were functional for at least 9 months before tPA, 12.5 µg, was injected into the anterior chamber. Eyes had longer than 6 months of follow-up after tPA use.

Results  Six eyes that had undergone phacoemulsification and 1 that had undergone penetrating keratoplasty were identified. Before the secondary surgery, blebs had been in place for 20.4 ± 9.3 months, with an intraocular pressure of 10.7 ± 3.6 mm Hg. New bleb failure in these eyes was observed following phacoemulsification or penetrating keratoplasty between postoperative days 4 and 14, with the intraocular pressure increasing to 27.7 ± 9.5 mm Hg. One day after tPA use, the intraocular pressure had decreased to 11.0 ± 3.7 mm Hg (P = .002). In 5 of the 7 patients, the bleb height improved following tPA use. The final intraocular pressure was 10.7 ± 3.6 mm Hg at a follow-up of 13.4 ± 6.4 months. (All data are given as mean ± SD.)

Conclusion  Tissue plasminogen activator can be a useful adjunct for reviving newly failing blebs after other anterior segment surgery.

From the Department of Ophthalmology, University of Florida, Gainesville. Neither of the authors has a financial interest in any product discussed in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(6):931-932.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tissue plasminogen activator therapy for the eye
Tripathi and Tripathi
Br J Ophthalmol 2005;89:1390-1391.
FULL TEXT  

Intracameral Tissue Plasminogen Activator Use in a Large Series of Eyes With Valved Glaucoma Drainage Implants
Zalta et al.
Arch Ophthalmol 2002;120:1487-1493.
ABSTRACT | FULL TEXT